Literature DB >> 19155238

Drug-induced cutaneous pathology.

P K Ramdial1, D K Naidoo.   

Abstract

Drug-induced cutaneous rashes, whether confined to the skin or part of a systemic disease, are characterised by a spectrum of inflammatory disease patterns that include perivascular dermatitis, nodular and diffuse dermatitis, vesiculobullous lesions, pustular eruptions, sclerodermoid reactions, vasculitis, folliculitis/perifolliculitis and panniculitis. While a single drug can elicit a range of reaction patterns, no reaction pattern is specific for a particular drug. Although the temporal link between initiation of drug therapy and the onset of the drug rash is critical to the diagnosis, drug reactions may also occur during the course of chronic drug ingestion. Clues to the drug-induced nature of the cutaneous eruption include the presence of overlapping histological reaction patterns and incongruent clinical and histopathological features. While eosinophils are an important tell-tale sign of a drug-induced reaction, they may also be conspicuous in skin rashes devoid of a drug association. Furthermore, eosinophils may be sparse or absent in some drug exanthems. Heightened awareness of the mimicry of a wide spectrum of cutaneous pathology by an ever-increasing range of therapeutic agents is pivotal to the diagnosis of drug-induced skin pathology.

Entities:  

Mesh:

Year:  2009        PMID: 19155238     DOI: 10.1136/jcp.2008.058289

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  9 in total

Review 1.  Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract.

Authors:  Dagmar Simon; Andrew Wardlaw; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2010-04-14       Impact factor: 10.793

2.  Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia.

Authors:  Aruna Gavini; Gladys H Telang; Adam J Olszewski
Journal:  Int J Hematol       Date:  2012-03       Impact factor: 2.490

3.  Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.

Authors:  Alexander Pan; Rachel E Reingold; Jimmy L Zhao; Andrea Moy; Lukas Kraehenbuehl; George Dranitsaris; Sean M McBride; Howard I Scher; Marisa A Kollmeier; Han Xiao; Dana E Rathkopf; Mario E Lacouture
Journal:  J Urol       Date:  2022-01-12       Impact factor: 7.600

Review 4.  Injection site reactions after subcutaneous oligonucleotide therapy.

Authors:  Leonie van Meer; Matthijs Moerland; Jolie Gallagher; Martijn B A van Doorn; Errol P Prens; Adam F Cohen; Robert Rissmann; Jacobus Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2016-05-31       Impact factor: 4.335

5.  Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital.

Authors:  Elena Ramírez; Nicolás Medrano-Casique; Hoi Y Tong; Teresa Bellón; Rosario Cabañas; Ana Fiandor; Jessica González-Ramos; Pedro Herranz; Elena Trigo; Mario Muñoz; Alberto M Borobia; Antonio J Carcas; Jesús Frías
Journal:  Br J Clin Pharmacol       Date:  2016-10-12       Impact factor: 4.335

6.  Deposition of immunoreactants in a cutaneous allergic drug reaction.

Authors:  Ana Maria Abreu-Velez; Billie L Jackson; Michael S Howard
Journal:  N Am J Med Sci       Date:  2009-09

7.  Romidepsin-induced neutrophilic urticaria.

Authors:  Brian Scott; Heather Wickless
Journal:  JAAD Case Rep       Date:  2016-07-14

8.  Amlodipine-Induced Subacute Cutaneous Lupus Erythematosus Localized to Non-Sun-Exposed Areas.

Authors:  Takahiro Mizuta; Miyuki Kato
Journal:  Case Rep Dermatol       Date:  2022-03-29

9.  Dermoscopic Aspects of Cutaneous Adverse Drug Reactions.

Authors:  Gabriela Rossi; André da Silva Cartell; Renato Marchiori Bakos
Journal:  Dermatol Pract Concept       Date:  2021-01-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.